X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs CIPLA - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA CIPLA TORRENT PHARMA/
CIPLA
 
P/E (TTM) x 27.2 44.6 61.1% View Chart
P/BV x 5.2 3.8 135.6% View Chart
Dividend Yield % 1.1 0.3 312.9%  

Financials

 TORRENT PHARMA   CIPLA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
CIPLA
Mar-17
TORRENT PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,768622 284.3%   
Low Rs1,186458 258.7%   
Sales per share (Unadj.) Rs346.1181.9 190.3%  
Earnings per share (Unadj.) Rs55.212.9 428.7%  
Cash flow per share (Unadj.) Rs73.329.3 250.1%  
Dividends per share (Unadj.) Rs14.002.00 700.0%  
Dividend yield (eoy) %0.90.4 256.0%  
Book value per share (Unadj.) Rs257.1155.7 165.1%  
Shares outstanding (eoy) m169.22804.51 21.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.33.0 143.7%   
Avg P/E ratio x26.842.0 63.8%  
P/CF ratio (eoy) x20.118.4 109.3%  
Price / Book Value ratio x5.73.5 165.6%  
Dividend payout %25.415.5 163.3%   
Avg Mkt Cap Rs m249,887434,516 57.5%   
No. of employees `00011.823.0 51.1%   
Total wages/salary Rs m9,93426,338 37.7%   
Avg. sales/employee Rs Th4,971.56,349.1 78.3%   
Avg. wages/employee Rs Th843.21,143.0 73.8%   
Avg. net profit/employee Rs Th792.4449.3 176.4%   
INCOME DATA
Net Sales Rs m58,569146,302 40.0%  
Other income Rs m2,2332,287 97.6%   
Total revenues Rs m60,802148,589 40.9%   
Gross profit Rs m13,77324,758 55.6%  
Depreciation Rs m3,06913,229 23.2%   
Interest Rs m2,0561,594 129.0%   
Profit before tax Rs m10,88112,222 89.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5451,798 86.0%   
Profit after tax Rs m9,33610,354 90.2%  
Gross profit margin %23.516.9 139.0%  
Effective tax rate %14.214.7 96.5%   
Net profit margin %15.97.1 225.2%  
BALANCE SHEET DATA
Current assets Rs m53,84187,370 61.6%   
Current liabilities Rs m31,61233,081 95.6%   
Net working cap to sales %38.037.1 102.3%  
Current ratio x1.72.6 64.5%  
Inventory Days Days9787 111.7%  
Debtors Days Days8462 134.4%  
Net fixed assets Rs m42,079111,567 37.7%   
Share capital Rs m8461,609 52.6%   
"Free" reserves Rs m42,655123,645 34.5%   
Net worth Rs m43,501125,254 34.7%   
Long term debt Rs m22,40836,454 61.5%   
Total assets Rs m101,250209,532 48.3%  
Interest coverage x6.38.7 72.6%   
Debt to equity ratio x0.50.3 177.0%  
Sales to assets ratio x0.60.7 82.8%   
Return on assets %11.35.7 197.3%  
Return on equity %21.58.3 259.6%  
Return on capital %19.68.5 230.9%  
Exports to sales %034.2 0.0%   
Imports to sales %08.3 0.0%   
Exports (fob) Rs mNA50,050 0.0%   
Imports (cif) Rs mNA12,203 0.0%   
Fx inflow Rs m20,06651,066 39.3%   
Fx outflow Rs m5,30417,678 30.0%   
Net fx Rs m14,76233,388 44.2%   
CASH FLOW
From Operations Rs m10,12723,824 42.5%  
From Investments Rs m-7,869-13,127 59.9%  
From Financial Activity Rs m-1,918-13,239 14.5%  
Net Cashflow Rs m212-2,478 -8.5%  

Share Holding

Indian Promoters % 71.5 16.0 446.9%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 7.0 12.2 57.5%  
FIIs % 12.6 23.7 53.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 8.8 26.2 33.6%  
Shareholders   26,511 161,166 16.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   SUVEN LIFE  SHASUN PHARMA  SANOFI INDIA  TTK HEALTHCARE  SUN PHARMA  

Compare TORRENT PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - BIOCON LTD COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS